Related content

Acceptability of the levonorgestrel releasing-intrauterine system and etonogestrel implant: One-year results of an observational study

By Short Mary   Dallay Dominique   Omokanye Salmon   Hanisch Jens Ulrich   Inki Pirjo  

The European Journal of Contraception and Reproductive Health Care, Vol. 17, Iss. 1, 2012-02 ,pp. : 79-88

Informa Healthcare

Access to resources Recommend Favorite

Compliance with hormone replacement therapy in menopausal women: results of a two-year prospective French study comparing transdermal treatment with fixed oral combination therapy

By Serfaty D.   de Reilhac P.   Eschwege E.   Ringa V.   Blin P.   Nandeuil A.   Tavera C.   Mathieu M.  

Gynecology Obstetrique & Fertilite, Vol. 31, Iss. 6, 2003-06 ,pp. : 525-533

Elsevier

Access to resources Recommend Favorite

Combined ethinylestradiol/gestodene contraceptive patch: two-center, open-label study of ovulation inhibition, acceptability and safety over two cycles in female volunteers

By Heger-Mahn D   Warlimont C   Faustmann T   Gerlinger C   Klipping C  

The European Journal of Contraception and Reproductive Health Care, Vol. 9, Iss. 3, 2004-09 ,pp. : 173-181

Informa Healthcare

Access to resources Recommend Favorite

Prevalence of CVD risk factors and impact of a two-year education program for premenopausal women

By Miller S.L.   Reber R.J.   Chapman-Novakofski K.  

Women's Health Issues, Vol. 11, Iss. 6, 2001-11 ,pp. : 486-493

Elsevier

Access to resources Recommend Favorite

Effect of the subdermal contraceptive etonogestrel implant (Implanon®) on biochemical and hormonal parameters (three years follow-up)

By Murat Inal M.   Yildirim Yusuf   Ertopcu Kenan   Eftal Avci M.   Ozelmas Isa   Tinar Sivekar  

The European Journal of Contraception and Reproductive Health Care, Vol. 13, Iss. 3, 2008-01 ,pp. : 238-242

Informa Healthcare

Access to resources Recommend Favorite